Oral Minoxidil Medicaid Coverage by State Tier (2026 Guide)

Does Medicaid cover oral minoxidil for hair loss?

This page has no state preferred drug lists, tier placements, prior authorization rules or step-therapy requirements, so it makes no claim about any named state. The federal status is this: minoxidil tablets are indicated only for hypertension that is symptomatic or associated with target organ damage and not manageable with maximum doses of a diuretic plus two other antihypertensive drugs, and the label says use in milder hypertension is not recommended [1].

What the label says about hair-growth use

The tablet label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication [1]. It also says extemporaneous compounded topical formulations have not been shown safe or effective and share the full contraindications, warnings and adverse reactions of the label, because systemic absorption can occur [1]. The minoxidil products marketed for hair regrowth are topical 2% and 5% solutions and a 5% foam, all labeled over the counter in Drugs@FDA, alongside generic OTC versions. Rogaine 2% solution switched from prescription to over-the-counter status with an approval dated 02/09/1996 [3].

Which tablets the FDA record covers

Loniten (Pfizer) was approved 10/18/1979 as a new molecular entity. Its 2.5 mg and 10 mg tablets are now marked Discontinued in Drugs@FDA, with an FDA determination that the discontinuation was not for safety or effectiveness reasons [2]. Generic minoxidil tablets approved under ANDAs, the earliest in 1987, remain on the market [2].

Safety facts

The oral tablet carries a boxed warning, written for antihypertensive doses: it can cause pericardial effusion, occasionally progressing to tamponade, and can exacerbate angina, so it is reserved for hypertensive patients who do not respond to maximum doses of a diuretic and two other antihypertensives [1]. At those doses hypertrichosis occurs in about 80% of patients and reverses over 1 to 6 months after stopping, with no endocrine abnormality found to explain it [1].

At low doses the reported profile differs. A retrospective multicenter study of 1404 patients treated for at least 3 months, with no control group, found hypertrichosis in 15.1%, lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9%, with no life-threatening adverse effects observed [4].